Cognitive Impairment Market

Market Overview:

The 7 major cognitive impairment markets reached a value of USD 3,482.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 7,094.2 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.72% during ​2025-2035​.

The cognitive impairment market has been comprehensively analyzed in IMARC's new report titled "Cognitive Impairment Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Cognitive impairment refers to a decline in cognitive abilities like memory, attention, and problem-solving skills. The severity of this ailment can range from mild to severe, with mild impairment potentially allowing individuals to still function in daily life. Common symptoms associated with cognitive impairment include amnesia, difficulty concentrating, difficulty finding words, increased irritability, anxiety, depression, withdrawal from social activities, confusion about time or location, and issues with reasoning or judgment. People with the disease may have difficulty with ordinary tasks such as following directions and maintaining social interactions. Diagnosis of cognitive impairment involves a detailed medical history, physical and neurological examinations, and cognitive assessments like the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). The healthcare providers may also recommend several brains imaging studies, including MRI or CT scans, to rule out structural abnormalities that could be causing cognitive problems. In some cases, a lumbar puncture may be performed to analyze CSF for markers of neurodegenerative diseases.

The escalating cases of traumatic brain injury that can disrupt the brain's ability to process information, leading to problems with memory, attention, and executive functions, are primarily driving the cognitive impairment market. In addition to this, the increasing utilization of cognitive stimulation therapy, since it focuses on stimulating and engaging the patient's neural abilities as well as promoting social interaction, is also creating a positive outlook for the market. Moreover, the widespread adoption of cholinesterase inhibitors, like donepezil, rivastigmine, galantamine, etc., to improve memory and thinking skills by increasing acetylcholine levels in the brain, is further bolstering the market growth. Apart from this, the rising usage of occupational therapy which can help to maintain independence in daily living activities and maximize functional performance, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of monoclonal antibodies, which are designed to target and reduce the accumulation of beta-amyloid plaques in the brain, thereby boosting cognitive outcomes, is expected to drive the cognitive impairment market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cognitive impairment market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cognitive impairment and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cognitive impairment market in any manner.

Recent Developments:

• In April 2025, Eisai Co., Ltd. and Biogen Inc. declared that the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) had been approved for marketing in the European Union by the European Commission (EC).
• In October 2024, Eli Lilly and Company stated that donanemab, an intravenous infusion injection administered every four weeks to treat mild cognitive impairment and mild dementia caused by Alzheimer's disease, had been approved for marketing by the Medicines and Healthcare Products Regulatory Agency (MHRA) in eligible adults in Great Britain.
• In October 2024, AgeneBio, Inc. published new findings from the HOPE4MCI Phase 2B study, presenting promising results for Alzheimer’s patients who do not carry an ApoE-4 allele. The trial evaluated the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease.

Drugs:

Leqembi (lecanemab) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). The drug selectively binds to soluble Aβ aggregates and insoluble Aβ aggregates (fibrils) that form plaques. By reducing these toxic forms of Aβ, Leqembi aims to slow the progression of Alzheimer's disease and improve cognitive function.

Kisunla (donanemab), a medication developed by Eli Lilly, works by targeting and removing specific forms of amyloid beta (Aβ) plaques in the brain. These plaques are a hallmark of Alzheimer's disease and are believed to contribute to cognitive decline. Donanemab specifically binds to the N-terminal, pyroglutamate-modified Aβ, found in mature amyloid plaques. By binding to these plaques, donanemab facilitates their removal through a process called microglial-mediated phagocytosis, where immune cells in the brain engulf and break down the plaques.

AGB101 is designed to address the overactivity of the hippocampus, a brain region crucial for memory and learning. This overactivity is a hallmark of mild cognitive impairment due to Alzheimer's disease and is considered to contribute to the spread of tau pathology and neurodegeneration. AGB101 binds to the SV2A receptor, a protein involved in the release of neurotransmitters from nerve cells. By binding to this receptor, AGB101 inhibits the release of neurotransmitters, thereby helping to reduce the overactivity in the hippocampus.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cognitive impairment market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cognitive impairment market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current cognitive impairment marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cognitive impairment market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the cognitive impairment across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the cognitive impairment across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of cognitive impairment across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of cognitive impairment by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of cognitive impairment by gender across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of cognitive impairment by type across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with cognitive impairment across the seven major markets?
• What is the size of the cognitive impairment patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend cognitive impairment of?
• What will be the growth rate of patients across the seven major markets?

Cognitive Impairment: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cognitive impairment drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cognitive impairment market?
• What are the key regulatory events related to the cognitive impairment market?
• What is the structure of clinical trial landscape by status related to the cognitive impairment market?
• What is the structure of clinical trial landscape by phase related to the cognitive impairment market?
• What is the structure of clinical trial landscape by route of administration related to the cognitive impairment market?